Recent studies have demonstrated that fibroblast growth factor 21 (FGF-21), a liver derived protein, is able to increase glucose uptake, as well as lower plasma triglyceride levels in an insulin-independent manner. FGF-21 suppresses glucagon release, thereby increasing insulin sensitivity, and reduces the amount of insulin production by pancreatic b-cells. Unlike insulin, which works in a rapid, hormone-like manner, FGF-21 activity requires several hours, indicating changes in gene expression. No significant weight gain was observed when FGF-21 was injected into animals, and mice that had been genetically engineered to overexpress FGF-21 weighed less and had less adipose tissue than the normal controls.
Although considerable progress has been made in the understanding of the pathobiology of type 2 diabetes, as well in the development of new compounds for the treatment of diabetic patients, this disease remains a major global health concern. The insulin-independent activities of FGF-21, as well as the absence of the weight gain effects of insulin, thiazolidinediones and other anti-diabetic drugs, distinguish it from current insulin-sensitizing drugs, making it a promising therapeutic.
Sensitivity: 49.4 pg/mL when using 10uL Mouse or 20uL Rat sample size.
Intra-assay: (same/less than) 10%
Inter-assay: (same/less than) 8%
Detection Method: Colorimetric
Standard Curve Range: 50-12000pg/ml
1. Rat/Mouse FGF-21 ELISA Plate 1x96 wells
2. HRP Wash Buffer Concentrate, 10X 2x50ml
3. Rat/Mouse FGF-21 Standard, 1x1 vial
4. Control A ,1x1 vial
5. Control B ,1x1 vial
6. Matrix Solution, 1x1vial
7. Assay Buffer, 1x25ml
8. Detection Antibody (biotin), 1x1.2ml
9. Enzyme Solution, 1x12ml
10. Substrate (3, 3